

ENTA · NASDAQ · WEEK ENDED 24 JUL 2026

Weekly Investor Report

Enanta Pharmaceuticals Inc · Healthcare · Biotechnology

LATEST CLOSE

12.78 USD

-7.0% latest week

Weekly setup

Weak trend

The weekly trend is not active. Price is -4.7% below the Trend Line and sits at 59.2% of its 52-week range. The latest completed week returned -7.0%, after a -8.7% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is bearish with 58/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Technical setup score 34/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

12.78 USD

24 Jul 2026

1W RETURN

-7.0%

latest completed week

4W RETURN

-8.7%

short-term follow-through

12W RETURN

-10.9%

quarterly tape

TREND BREADTH

84.6%

44 of 52 weeks active

VOLUME RATIO

0.7x

vs 13-week average

What is working

- Price is above Fair Value, showing premium demand versus the model.

What could go wrong

- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Activity pressure is negative, which weakens the current setup.
- Activity pressure is weak, so confirmation is not yet broad enough.

What to watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

-7.0%

Latest completed week; four-week move -8.7%.

INDICATOR STACK

47/49

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

Copyright 2026 Sharemaestro · Educational market research · sharemaestro.com

Page 1

Not financial advice. Market and fundamental data may be delayed, incomplete, or inaccurate. See the full disclosure on the final page.

OPTIONS PRESSURE

Bearish

58/100 conviction; expected move 16.4%.

NEWS SENTIMENT

51/100

65 relevant articles in the latest sentiment read.

EVENT RISK

11d


Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -4.7% below the Trend Line and sits at 59.2% of its 52-week range. The latest completed week returned -7.0%, after a -8.7% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range Fair Close Trend 6.45 USD 17.15 USD Latest close sits at 59.2% of the 52-week range.	RANGE LOCATION 59.2% Shows where the latest close sits between the 52-week low and high.	TREND DISTANCE -4.7% Price premium or discount versus the weekly Trend Line.
	FAIR-VALUE GAP 16.0% Premium demand or model discount versus Sharemaestro Fair Value.	HIGH-WATER GAP -25.5% Distance from the latest 52-week high.


02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



Demand beneath price

Activity pressure and institutional-style signals


These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.



03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is -8.7% over four weeks, -10.9% over 12 weeks, and 72.7% over one year. The current trend has remained active for 0 consecutive weeks.



Technical setup scorecard

Trend		47
Momentum		20
Activity Pressure		49
Relative Leadership		21
Next-Week Expectancy		50
Volume		29
Smart Money		44
Risk Control		11

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

FACTOR WEEK 26 Jul 2026 Latest published factor snapshot.	STATEMENTS THROUGH 30 Sep 2025 Financial reporting period used.	FIELD COVERAGE 82% Available factor fields.	MODEL CONFIDENCE 78% Snapshot confidence.
--	--	--	--

Relative factor standing		
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.		
Overall factor strength		25/100
Value		23/100
Quality		15/100
Momentum		92/100
Growth		37/100

Valuation How much investors are paying for earnings, sales, and cash flow.	Business quality Margins and the return generated on invested capital.
P/E - Price divided by trailing earnings.	GROSS MARGIN 98.3% Gross profit retained from each unit of revenue.
PRICE / SALES 5.4x Market value relative to trailing revenue.	OPERATING MARGIN -74.4% Operating profit retained from revenue.
EV / EBITDA - Enterprise value relative to operating cash earnings.	FREE-CASH-FLOW MARGIN -8.8% Free cash flow generated from revenue.
FREE-CASH-FLOW YIELD -1.2% Free cash flow as a share of enterprise value.	RETURN ON INVESTED CAPITAL -14.4% Operating return generated on invested capital.

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength	Shareholder return and balance sheet
Recent business growth and accounting strength.	Cash returned to owners and financial leverage.
REVENUE GROWTH7.4%	DIVIDEND YIELD-
Latest one-year revenue growth.	Cash dividends relative to market value.
EPS GROWTH-	BUYBACK YIELD-0.0%
Latest one-year earnings-per-share growth.	Net share repurchases relative to market value.
FREE-CASH-FLOW GROWTH-	SHAREHOLDER YIELD-0.0%
Latest one-year free-cash-flow growth.	Dividend yield plus net buyback yield.
PIOTROSKI F-SCORE3/9	NET DEBT / EBITDA-3.3x
Nine-point accounting-strength checklist.	Balance-sheet debt relative to operating cash earnings.

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Bearish

ENTA shows bearish options pressure with a 58/100 conviction score, put-call volume ratio of n/a, expected move of 16.4%, and Sharemaestro trend signal inactive.

CONVICTION

58/100

Options signal conviction.

EXPECTED MOVE

16.4%

Nearest-chain pricing.

PUT/CALL VOLUME

0.00

Contract volume balance.

Pressure

-100

Speculation

0

Volatility

69

Trend agreement

36

News sentiment

51/100

Weighted news tone is neutral across 65 relevant articles.

10 positive · 50 neutral · 5 negative

Insider activity

-

No recent insider transactions are stored.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal

Copyright 2026 Sharemaestro · Educational market research · sharemaestro.com

Page 8

Not financial advice. Market and fundamental data may be delayed, incomplete, or inaccurate. See the full disclosure on the final page.

06 · CATALYSTS AND RISK


What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.	OPTIONS EXPECTED MOVE 16.4% Nearest-chain priced movement where available.	52-WEEK DRAWDOWN -25.5% Distance below the 52-week high.	13-WEEK VOLATILITY 8.3% Standard deviation of weekly returns.
--	--	--	---

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER

13 of 26

13 weeks finished lower.

BEST WEEK

+10.6%

Week of 26 Jun.

WORST WEEK

-14.3%

Week of 5 Jun.

LATEST WEEK

-7.0%

Week of 24 Jul.

Shape of recent returns

Strong gains		11
Modest gains		2
Flat weeks		-
Modest losses		5
Sharp losses		8

RECENT VOL

8.3%

13-week weekly-return volatility.

BASE VOL

8.0%

52-week weekly-return volatility.

UP/DOWN SPLIT

29/23

Count of positive and negative weeks in the 52-week window.

AVERAGE SKEW

7.0% / -5.7%

Average positive week versus average negative week.

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK - / 100 Standing within the tracked group.	GROUP AVERAGE 1.3% Average four-week return.	TREND BREADTH 51.0% Share of peers with an active trend.
--	--	--

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Biotechnology

4-WEEK RANK - / 100 Standing within the tracked group.	GROUP AVERAGE 0.5% Average four-week return.	TREND BREADTH 67.0% Share of peers with an active trend.
--	--	--

Peer	Exchange	1W return	4W return	Trend
CRNX	NASDAQ	-0.2%	128.1%	Active
ABVX	NASDAQ	-8.0%	28.9%	Active
BBIO	NASDAQ	3.2%	19.6%	Active
ERAS	NASDAQ	-0.3%	19.4%	Active
IOVA	NASDAQ	-0.2%	17.4%	Active

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	37/100	Trend, activity pressure, participation, and risk combine to a 37/100 tape read.	
Indicator analysis	39/100	Latest 12-week confirmation: trend 4/12, activity pressure 4/12, relative leadership 6/12.	Activity pressure 0.34; No reversal markers
Factors	35/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 70; Small Cap Core rank 80
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	31/100	ENTA shows bearish options pressure with a 58/100 conviction score, put-call volume ratio of n/a, expected move of 16.4%, and Sharemaestro trend signal inactive.	Bearish · Put-side pressure · Expected move 16.4%
Sentiment	51/100	Weighted news tone is neutral across 65 relevant articles.	Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis
Insiders	50/100	No recent insider transaction evidence is stored.	Not currently available.
Earnings	11d	Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH -7.0% Latest completed week; four-week move -8.7%.	INDICATOR STACK 47/49 Trend and activity pressure are weighted against the latest 12-week confirmation window.	TREND BACKDROP Active The trend backdrop defines the current weekly regime.	PATIENT CAPITAL Quiet Activity-pressure buy-signal status for institutional accumulation timing.
OPTIONS PRESSURE Bearish 58/100 conviction; expected move 16.4%.	NEWS SENTIMENT 51/100 65 relevant articles in the latest sentiment read.	EVENT RISK 11d Next report is scheduled for 10 Aug 2026; event risk rises as the date approaches.	

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	12.78 USD	-7.0%	13.40 USD	11.02 USD	-0.29	-4.27	716.7K	Off
17 Jul 2026	13.74 USD	0.3%	13.54 USD	11.06 USD	0.01	1.84	727.7K	Off
10 Jul 2026	13.70 USD	-9.3%	13.59 USD	11.09 USD	-0.03	-2.07	1.1M	Off
03 Jul 2026	15.11 USD	7.9%	13.63 USD	11.12 USD	-0.19	10.74	1.1M	Off
26 Jun 2026	14.00 USD	10.6%	13.61 USD	11.15 USD	-0.56	4.22	2.0M	Off
19 Jun 2026	12.66 USD	6.4%	13.62 USD	11.20 USD	-0.69	-9.44	682.2K	Off
12 Jun 2026	11.90 USD	5.5%	13.62 USD	11.26 USD	-0.52	-12.30	885.9K	Off
05 Jun 2026	11.28 USD	-14.3%	13.62 USD	11.34 USD	-0.30	-14.75	1.1M	Off
29 May 2026	13.16 USD	-5.7%	13.61 USD	11.43 USD	0.15	-4.85	979.5K	On
22 May 2026	13.95 USD	4.0%	13.54 USD	11.52 USD	0.17	4.47	907.3K	On
15 May 2026	13.41 USD	-12.6%	13.43 USD	11.59 USD	0.00	2.49	1.3M	On
08 May 2026	15.34 USD	6.9%	13.35 USD	11.67 USD	-0.08	17.82	1.2M	On
01 May 2026	14.35 USD	7.8%	13.20 USD	11.73 USD	-0.41	17.61	637.5K	On
24 Apr 2026	13.31 USD	-5.0%	13.07 USD	11.87 USD	-0.63	11.85	585.0K	On

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.

Open the live report · Open the interactive chart · Full disclaimer